(60 days)
Not Found
Not Found
No
The document describes a susceptibility testing system and its intended use, focusing on limitations and manual reading requirements. There is no mention of AI or ML in the provided text.
No
The device is described as an "in vitro diagnostic product" for "clinical susceptibility testing," which means it's used to diagnose or aid in diagnosis, not to treat a condition.
Yes
The "Intended Use / Indications for Use" section explicitly states that the Sensititre system "is an in vitro diagnostic product for clinical susceptibility testing."
No
The device description explicitly states "Susceptibility Test Panel," which is a physical, in vitro diagnostic product, not software. The 510(k) is for modifying limitations related to reading this physical panel.
Yes, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states: "The Sensititie 18 - 24 hour MIC or Breakpoint Susceptibility System is an in vitro diagnostic product for clinical susceptibility testing of gram negative and gram positive organisms."
N/A
Intended Use / Indications for Use
The Sensititie 18 - 24 hour MIC or Breakpoint Susceptibility System is an in vitro diagnostic product for clinical susceptibility testing of gram negative and gram positive organisms.
This 510(k) is for the elimination of limitations in the sensititre technical insert. The limitation to be removed are as follows:
-
- The AutoReader system should not be used to read coagulase-negative Staphylococcus Species as they will not generate adequate signal to give a susceptibility result. Such strains should be read manually.
Maintain limitation 8 with a modification:
Staphylococcus Species - tested against Penicillin G. Should also be tested for Beta lactamase production, especially in strains with borderline MIC's (0.06 -- 0.25 µg/ml). If these strains test Beta Lactamase positive a repeat test should be done to ensure resistance is reported.
The addition of the following limitation in the Sensititre Technical Insert:
The Autoreader system should not be used to read SXT with CNS. SXT should be read manually.
Product codes
JWY
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.1640 Antimicrobial susceptibility test powder.
(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).
0
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is a stylized image of an eagle with its wings spread. The eagle is facing to the right.
od and Drug Administra 98 Gaither Road ockville MD 20850
Ms. Cynthia C. Knapp Director of Lab Services Trek Diagnostic Systems, Inc. 29299 Clemens Road, Suite 1-K Westlake, OH 44145
Re: K022656
Trade/Device Name: Susceptibility Test Panel Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial Susceptibility Test Regulatory Class: Class II Product Code: JWY Dated: August 2, 2002 Received: August 9, 2002
Dear Ms. Knapp:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
Page 2 - -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
n510 (k) Number (If kno
Device Name: Susceptibility Test Panel
Indications For Use:
The Sensititie 18 - 24 hour MIC or Breakpoint Susceptibility System is an in vitro diagnostic product
for clinical susceptibility testing of gram negative and gram positive organisms.
This 510(k) is for the elimination of limitations in the sensititre technical insert. The limitation to be removed are as follows:
-
- The AutoReader system should not be used to read coagulase-negative Staphylococcus Species as they will not generate adequate signal to give a susceptibility result. Such strains should be read manually.
Maintain limitation 8 with a modification:
Staphylococcus Species - tested against Penicillin G. Should also be tested for Beta lactamase production, especially in strains with borderline MIC's (0.06 -- 0.25 µg/ml). If these strains test Beta Lactamase positive a repeat test should be done to ensure resistance is reported.
The addition of the following limitation in the Sensititre Technical Insert:
The Autoreader system should not be used to read SXT with CNS. SXT should be read manually.
(PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| (Division Sign-Off) | |
|---|---|
| Division of Clinical Laboratory Devices | |
| 510(k) Number | K02 2657 |
Prescription Use (Per 21 CFR 801 109
ાર
Over-The-Counter Use